Veristat Congratulates Agios on the FDA Approval of TIBSOVO®
The First Targeted Therapy for Adult Patients with Relapsed/Refractory Acute Myeloid Leukemia and an IDH1 Mutation
SOUTHBOROUGH, MA –...
SOUTHBOROUGH, MA –...